ATRS-1701

ATRS-1701 is an investigational **combination drug-device** product developed by Antares Pharma for an undisclosed **neurology** indication. Publicly available information indicates that it was part of Antares Pharma's proprietary pipeline and appears to have been positioned as an emergency-use or rescue-style injectable product leveraging the company's self-administered injection technology platform, but the active pharmaceutical ingredient, precise target, and detailed clinical profile were not publicly disclosed. Available pipeline sources classify it as a **small molecule** program in nervous system disease and indicate that development was ultimately **discontinued or terminated**.